# Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis

@article{Lindholm2005ShouldB,
title={Should $\beta$ blockers remain first choice in the treatment of primary hypertension? A meta-analysis},
author={Lars H. Lindholm and Bo Carlberg and Ola Samuelsson},
journal={The Lancet},
year={2005},
volume={366},
pages={1545-1553}
}
• Published 29 October 2005
• Medicine
• The Lancet
BACKGROUND Beta blockers have been used widely in the treatment of hypertension and are recommended as first-line drugs in hypertension guidelines. However, a preliminary analysis has shown that atenolol is not very effective in hypertension. We aim to substantially enlarge the data on atenolol and analyse the effect of different beta blockers. METHODS The Cochrane Library and PubMed were searched for beta blocker treatment in patients with primary hypertension. Data were then entered into… Expand
718 Citations
How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis
• Medicine
• Journal of hypertension
• 2006
Beta-blockers are inferior to CCBs and to RAS inhibitors for reducing several important hard end points and are generally suboptimal first-line antihypertensive drugs. Expand
Beta blockers in primary hypertension: Do age and type of beta-blocker matter?
• Medicine
• Journal of hypertension
• 2006
It is concluded that beta blockers should not remain the first choice in the treatment of primary hypertension because they clearly have a suboptimum effect and the finding of the network meta-analysis by Psaty and colleagues that low-dose diuretics do better than beta blockers is strengthened. Expand
Re-examining the efficacy of β-blockers for the treatment of hypertension: a meta-analysis
• Medicine
• 2006
β-blockers should not be considered first-line therapy for older hypertensive patients without another indication for these agents; however, in younger patients β-blocker are associated with a significant reduction in cardiovascular morbidity and mortality. Expand
β-Blockers in hypertension: studies and meta-analyses over the years.
• Medicine
• The Canadian journal of cardiology
• 2014
Clinicians better understand the role of β-blockers in managing hypertension by reviewing 17 large trials influencing the recommendations on the use of these agents in the treatment of hypertension. Expand
Beta‐blockers as sub‐optimal treatment for hypertension: Time for first‐line therapy revision?
• Medicine
• Blood pressure
• 2006
Results of LIFE and other recent studies, including the above-mentioned meta-analyses, support using newer comparators in future trials, and the weight of evidence strongly suggests that sympathetic over-activity is important in the etiology and maintenance of hypertension. Expand
Should beta-blockers still be used as initial antihypertensive agents in uncomplicated hypertension?
• A. Wu
• Medicine
• Annals of the Academy of Medicine, Singapore
• 2007
In conclusion, beta-blockers should not be the first drugs of choice in the management of uncomplicated hypertension, but they may be used in addition to other antihypertensive agents to achieve blood pressure goals. Expand
Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis.
• Medicine
• The Canadian journal of cardiology
• 2014
In the young, both atenolol and nonatenolol β-blockers are effective in reducing cardiovascular end points for hypertension without compelling indications. Expand
Beta-blockers in the treatment of hypertension: latest data and opinions.
• Medicine
• Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
• 2008
The historical course of the use of beta-blockers in the treatment of hypertension up to the present day is illuminated, the most recent data from meta-analyses that have downgraded them from antihypertensive drugs of first choice are presented, and the different views expressed are discussed. Expand
Should β Blockers No Longer Be Considered First-line Therapy for the Treatment of Essential Hypertension Without Comorbidities?
• Medicine
• Current cardiology reports
• 2011
Whether initial β blockers newer than atenolol reduce cardiovascular risk to the same extent as other antihypertensive drugs should be answered with more clinical trials. Expand
Prevention of risk factors: beta-blockade and hypertension
Beta-blockers should be avoided in patients with a high risk of incident diabetes, and in those with contraindications, but they remain drugs of crucial importance in other common clinical situations, e.g. in hypertensive patients with angina pectoris, post-myocardial infarction, and heart failure. Expand

#### References

SHOWING 1-10 OF 55 REFERENCES
Are β-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?: A Systematic Review
• Medicine
• 1998
Diuretic therapy was superior to β-blockade with regard to all end points and was effective in preventing cerebrovascular events but was ineffective in preventing coronary heart disease, cardiovascular mortality, and all-cause mortality. Expand
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.
• Medicine
• The American journal of medicine
• 2003
A meta-analysis of double-blind trials that measured the effects of antihypertensive therapy on left ventricular mass found that angiotensin II receptor antagonists, calcium antagonists, and ACE inhibitors were more effective at reducing left Ventricular mass than were beta-blockers. Expand
Atenolol in hypertension: is it a wise choice?
• Medicine
• The Lancet
• 2004
The results cast doubts on atenolol as a suitable drug for hypertensive patients and challenge the use of atenolia as a reference drug in outcome trials in hypertension. Expand
Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial.
Antihypertensive treatment based on a beta-blocker or on a thiazide diuretic could not be shown to affect the prevention of hypertensive complications, including CHD, to a different extent. Expand
Cardiovascular protection and blood pressure reduction: a meta-analysis
• Medicine
• The Lancet
• 2001
Meta-regression showed that odds ratios could be explained by achieved differences in systolic pressure, and all antihypertensive drugs have similar long-term efficacy and safety. Expand
[Should beta-blockers remain first choice in the treatment of primary hypertension?].
• Medicine
• Medicina clinica
• 2007
It is concluded that beta-blockers lead to an increased risk of stroke compared with other anti-hypertensive drugs and a decreased risk of Stroke compared with placebo. Expand
β Blockade after myocardial infarction: systematic review and meta regression analysis
• Medicine
• 1999
β Blockers are effective in long term secondary prevention after myocardial infarction, but they are underused in such cases and lead to avoidable mortality and morbidity. Expand
beta-Blockers in hypertension-the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension.
• Medicine
• American journal of hypertension
• 2003
The time has come to admit that beta-blockers should no longer be considered appropriate for first-line therapy in uncomplicated hypertension, due to a lack of efficacy and multiple adverse effects. Expand
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
Beta-blocker therapy had benefits for survival in stable heart-failure patients and should not be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients. Expand
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study
Diltiazem was as effective as treatment based on diuretics, beta-blockers, or both in preventing the combined primary endpoint of all stroke, myocardial infarction, and other cardiovascular death. Expand